MIM
ABCL icon

MetLife Investment Management’s AbCellera Biologics ABCL Stock Holding History

MetLife Investment Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-109,657
Closed -$827K – 2938
2023
Q1 		$827K Hold
109,657
– – 0.01% 1332
2022
Q4 		$1.11M Sell
109,657
-3,084
-3% -$35.6K 0.01% 1173
2022
Q3 		$1.12M Buy
112,741
+3,554
+3% +$39K 0.01% 1129
2022
Q2 		$1.16M Buy
+109,187
New +$924K 0.01% 1134

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

MetLife Investment Management's ABCL Position: Q2 2023 in Review

MetLife Investment Management sold out of AbCellera Biologics (ABCL) in Q2 2023, closing a stake of 109,657 shares — an estimated $827K sold.

MetLife Investment Management first reported a position in ABCL in Q2 2022 and held it in 4 quarters. The position peaked at $1.16M in Q2 2022. 169 funds tracked by Wall St. Rank hold ABCL as of Q2 2023.

  • MetLife Investment Management reported no remaining AbCellera Biologics position as of Q2 2023 after selling out during the quarter.
  • MetLife Investment Management sold 109,657 AbCellera Biologics shares in Q2 2023, an estimated $827K.
  • MetLife Investment Management first reported a position in AbCellera Biologics in Q2 2022 and held it in 4 quarters.
  • MetLife Investment Management's AbCellera Biologics position peaked at $1.16M in Q2 2022.
  • 169 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2023.

Based on MetLife Investment Management's 13F filing for Q2 2023, filed 10 Aug 2023.